Virtual Library
Start Your Search
S. Zhou
Author of
-
+
P3.04 - Clinical Design, Statistics and Clinical Trials (ID 720)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Clinical Design, Statistics and Clinical Trials
- Presentations: 1
- Moderators:
- Coordinates: 10/18/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P3.04-007 - A Prospective Study of Apatinib in Advanced Small Cell Lung Cancer Patients Failed from Two or More Lines of Chemotherapy (ID 10041)
09:30 - 09:30 | Author(s): S. Zhou
- Abstract
Background:
Small cell lung cancer (SCLC) is an aggressive and invasive variant of lung tumors，and its treatment strategy is poor. Apatinib is an oral TKI against VEGFR-2. We determined the efficacy of Apatinib as third- or later-line treatment in advanced SCLC.
Method:
The study was expected to enroll 30 patients diagnosed with advanced SCLC. Patients received oral Apatinib 500mg QD and make an efficacy evaluation after first cycle, then every two cycles once again. The primary endpoint was progression-free-survival (PFS).
Result:
From November 10, 2016 to June 18, 2017, 10 patients were enrolled. 1 patient showed PR when make efficacy evaluation the first time, 8 patients were evaluated SD and 1 patient showed PD due to liver metastasis. Although only one patient showed PR, all the patients’ target lesions were reduced, as figure 1. Figure 1 Up to June 18, 4 patients out of the group due to PD, the PFS is 28 weeks, 19.8 weeks, 13 weeks and 4.7 weeks respectively. Another 6 patients are still investigated, as figure 2, the blue bars are their PFS . Figure 2
Conclusion:
Apatinib in advanced SCLC is worth expecting.To further investigate the role of Apatinib in SCLC patients, large sample and additional clinical trials are needed.
